ClinicalTrials.Veeva

Menu
C

CenExel Clinical Research | CBH Health

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEP-363856
Rapastinel
Esketamine
BHV-7000
Cariprazine
Risperidone
Aticaprant
Ralmitaront
RO6889450
KarXT

Parent organization

This site is a part of CenExel Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 51 total trials

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant (VENTURA-7)

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling
Anhedonia
Depressive Disorder, Major
Drug: Aticaprant
Other: Placebo

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Other: Placebo
Drug: Aticaprant

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that sw...

Invitation-only
Schizophrenia
Drug: SEP-363856

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.

Active, not recruiting
Bipolar Disorder
Drug: Placebo
Drug: BHV-7000

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Invitation-only
Bipolar Disorder
Drug: BHV-7000

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole
Locations recently updated

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Otsuka logo
Allergan logo
Biohaven logo
Merck Sharp & Dohme (MSD) logo
AbbVie logo
R
Roche logo
Biohaven logo
Karuna Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems